Riociguat
Brand name: Adempas
Rank #79 of 500 drugs by total cost
$236.6M
Total Cost
17,620
Total Claims
$236.6M
Total Cost
407
Prescribers
$13K
Cost per Claim
904
Beneficiaries
17,661
30-Day Fills
$581K
Avg Cost/Provider
43
Avg Claims/Provider
About Riociguat
Riociguat (sold as Adempas) was prescribed 17,620 times by 407 Medicare Part D providers in 2023, costing the program $236.6M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 76 | Dolutegravir Sodium (Tivicay) | $251.7M | 102,995 |
| 77 | Abemaciclib (Verzenio) | $242.2M | 16,125 |
| 78 | Abacavir/Dolutegravir/Lamivudi (Triumeq) | $238.1M | 61,147 |
| 79 | Riociguat (Adempas) | $236.6M | 17,620 |
| 80 | Elviteg/Cob/Emtri/Tenof Alafen (Genvoya) | $236.5M | 56,626 |
| 81 | Emtricitabine/Tenofov Alafenam (Descovy) | $222.4M | 94,580 |
| 82 | Immun Glob G(Igg)/Gly/Iga Ov50 (Gammagard Liquid) | $222.1M | 22,768 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology